Annovis Bio (ANVS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.99, -5.39% vs the prior close of $1.05.
- Volume 641.42K shares, 0.7x its 50-day average.
- New SEC filings: SCHEDULE 13G/A (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
ANVS slides 5.4% to $0.99, a 52-week low. Closed at $0.99, -5.39% vs the prior close of $1.05. Day range $0.99–$1.08, opened at $1.06.
ANVS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ANVS slides 5.4% to $0.99, a 52-week low
- Closed at $0.99, -5.39% vs the prior close of $1.05. Day range $0.99–$1.08, opened at $1.06.
- Volume was 641.42K shares, 0.7x its 50-day average of 934.46K.
- Price is -30.2% vs its 50-day average ($1.42) and -51.5% vs its 200-day average ($2.05).
- 52-week range $0.99–$5.50; today's close sits at 0% of that range, 81.9% below the 52-week high.
Oct 15, 2026 — ANVS rises 2.9% to $1.05
- Closed at $1.05, +2.94% vs the prior close of $1.02. Day range $1.01–$1.08, opened at $1.04.
- Volume was 572.20K shares, 0.6x its 50-day average of 945.02K.
- Price is -27.1% vs its 50-day average ($1.44) and -49.0% vs its 200-day average ($2.06).
- 52-week range $1.01–$5.50; today's close sits at 1% of that range, 80.9% below the 52-week high.
Oct 14, 2026 — ANVS slides 3.8% to $1.02, a 52-week low, 3 down days in a row
- Closed at $1.02, -3.77% vs the prior close of $1.06. Day range $1.01–$1.08, opened at $1.05.
- Volume was 844.20K shares, 0.9x its 50-day average of 944.32K.
- Price is -30.0% vs its 50-day average ($1.46) and -50.7% vs its 200-day average ($2.07).
- 52-week range $1.01–$5.50; today's close sits at 0% of that range, 81.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ANVS slides 7.8% to $1.06
- Closed at $1.06, -7.83% vs the prior close of $1.15. Day range $1.05–$1.15, opened at $1.15.
- Volume was 850.80K shares, 0.9x its 50-day average of 936.51K.
- Price is -28.1% vs its 50-day average ($1.47) and -49.1% vs its 200-day average ($2.08).
- 52-week range $1.04–$5.50; today's close sits at 0% of that range, 80.7% below the 52-week high.
Oct 12, 2026 — ANVS slides 5.0% to $1.15
- Closed at $1.15, -4.96% vs the prior close of $1.21. Day range $1.14–$1.21, opened at $1.21.
- Volume was 460.20K shares, 0.5x its 50-day average of 934.36K — lighter than usual.
- Price is -22.6% vs its 50-day average ($1.49) and -45.2% vs its 200-day average ($2.10).
- 52-week range $1.04–$5.50; today's close sits at 2% of that range, 79.1% below the 52-week high.
Oct 9, 2026 — ANVS jumps 3.4% to $1.21
- Closed at $1.21, +3.42% vs the prior close of $1.17. Day range $1.14–$1.24, opened at $1.17.
- Volume was 521.90K shares, 0.6x its 50-day average of 931.69K — lighter than usual.
- Price is -19.3% vs its 50-day average ($1.50) and -42.6% vs its 200-day average ($2.11).
- 52-week range $1.04–$5.50; today's close sits at 4% of that range, 78.0% below the 52-week high.
Oct 8, 2026 — ANVS slides 3.3% to $1.17
- Closed at $1.17, -3.31% vs the prior close of $1.21. Day range $1.14–$1.21, opened at $1.21.
- Volume was 815.40K shares, 0.9x its 50-day average of 926.74K.
- Price is -22.5% vs its 50-day average ($1.51) and -44.9% vs its 200-day average ($2.12).
- 52-week range $1.04–$5.50; today's close sits at 3% of that range, 78.7% below the 52-week high.
Oct 7, 2026 — ANVS rises 2.5% to $1.21
- Closed at $1.21, +2.54% vs the prior close of $1.18. Day range $1.16–$1.23, opened at $1.17.
- Volume was 429.70K shares, 0.5x its 50-day average of 932.53K — lighter than usual.
- Price is -20.4% vs its 50-day average ($1.52) and -43.3% vs its 200-day average ($2.13).
- 52-week range $1.04–$5.50; today's close sits at 4% of that range, 78.0% below the 52-week high.
Oct 6, 2026 — ANVS dips 1.7% to $1.18
- Closed at $1.18, -1.67% vs the prior close of $1.20. Day range $1.17–$1.24, opened at $1.20.
- Volume was 538.70K shares, 0.6x its 50-day average of 931.70K — lighter than usual.
- Price is -22.9% vs its 50-day average ($1.53) and -45.0% vs its 200-day average ($2.15).
- 52-week range $1.04–$5.50; today's close sits at 3% of that range, 78.5% below the 52-week high.
Oct 5, 2026 — ANVS rises 1.7% to $1.20
- Closed at $1.20, +1.69% vs the prior close of $1.18. Day range $1.14–$1.20, opened at $1.16.
- Volume was 657.60K shares, 0.7x its 50-day average of 939.23K.
- Price is -22.1% vs its 50-day average ($1.54) and -44.4% vs its 200-day average ($2.16).
- 52-week range $1.04–$5.50; today's close sits at 4% of that range, 78.2% below the 52-week high.
Oct 2, 2026 — ANVS rises 0.9% to $1.18
- Closed at $1.18, +0.85% vs the prior close of $1.17. Day range $1.14–$1.20, opened at $1.19.
- Volume was 648.50K shares, 0.7x its 50-day average of 938.87K.
- Price is -23.8% vs its 50-day average ($1.55) and -45.7% vs its 200-day average ($2.17).
- 52-week range $1.04–$5.50; today's close sits at 3% of that range, 78.5% below the 52-week high.
ANVS latest news & SEC filings
Every SEC filing by or about ANVS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 7, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Sep 11, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 25, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$14.82M (prior year -$6.22M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.40 (prior year -$0.32) (loss widened vs Jun 30, 2025)
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade ANVS
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, Mar 16, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.85% (largest 7.9%). That is a volatile stock.
- Liquidity: about 771.28K shares (≈$766.19K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.99 vs a range of $0.99–$5.50 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Michael B Hoffman bought 54,933 shares on May 20, 2026.
- Latest filings: 10-Q Aug 14, 2026; 8-K Aug 14, 2026; 8-K Jul 10, 2026.
- Share count: 42.61M shares outstanding (Aug 14, 2026), +118.6% vs a year earlier — notable dilution.
- Listing: NYSE · industry: Pharmaceutical Preparations.
ANVS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.06 | 1.08 | 0.99 | 0.99 | 641.42K |
| Oct 15, 2026 | 1.04 | 1.08 | 1.01 | 1.05 | 572.20K |
| Oct 14, 2026 | 1.05 | 1.08 | 1.01 | 1.02 | 844.20K |
| Oct 13, 2026 | 1.15 | 1.15 | 1.05 | 1.06 | 850.80K |
| Oct 12, 2026 | 1.21 | 1.21 | 1.14 | 1.15 | 460.20K |
| Oct 9, 2026 | 1.17 | 1.24 | 1.14 | 1.21 | 521.90K |
| Oct 8, 2026 | 1.21 | 1.21 | 1.14 | 1.17 | 815.40K |
| Oct 7, 2026 | 1.17 | 1.23 | 1.16 | 1.21 | 429.70K |
| Oct 6, 2026 | 1.20 | 1.24 | 1.17 | 1.18 | 538.70K |
| Oct 5, 2026 | 1.16 | 1.20 | 1.14 | 1.20 | 657.60K |
| Oct 2, 2026 | 1.19 | 1.20 | 1.14 | 1.18 | 648.50K |
| Oct 1, 2026 | 1.27 | 1.28 | 1.16 | 1.17 | 1.20M |
| Sep 30, 2026 | 1.30 | 1.34 | 1.27 | 1.27 | 572.50K |
| Sep 29, 2026 | 1.39 | 1.41 | 1.30 | 1.30 | 812.00K |
| Sep 28, 2026 | 1.32 | 1.43 | 1.30 | 1.38 | 1.19M |
| Sep 25, 2026 | 1.35 | 1.36 | 1.31 | 1.31 | 573.50K |
| Sep 24, 2026 | 1.27 | 1.34 | 1.23 | 1.33 | 853.90K |
| Sep 23, 2026 | 1.30 | 1.33 | 1.24 | 1.27 | 1.14M |
| Sep 22, 2026 | 1.19 | 1.30 | 1.19 | 1.26 | 1.21M |
| Sep 21, 2026 | 1.16 | 1.22 | 1.16 | 1.19 | 882.30K |
About Annovis Bio
Annovis Bio (ANVS) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in MALVERN, PA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1477845.
ANVS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Claudine Bruck | Director | Nov 12, 2025 |
| Michael B Hoffman | Director | May 21, 2026 |
| Maria-Luisa Maccecchini | President & CEO | Nov 12, 2025 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Maria-Luisa Maccecchini | President & CEO | Nov 12, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 20, 2026 | Michael B Hoffman | Buy | 54,933 | $1.90 |
| May 20, 2026 | Michael B Hoffman | Buy | 2,562 | $1.75 |
| May 20, 2026 | Michael B Hoffman | Buy | 18,849 | $1.80 |
| May 20, 2026 | Michael B Hoffman | Buy | 54,933 | $1.90 |
| May 20, 2026 | Michael B Hoffman | Buy | 2,562 | $1.75 |
| May 20, 2026 | Michael B Hoffman | Buy | 18,849 | $1.80 |
| May 20, 2026 | Michael B Hoffman | Buy | 54,933 | $1.90 |
| May 20, 2026 | Michael B Hoffman | Buy | 2,562 | $1.75 |
| May 20, 2026 | Michael B Hoffman | Buy | 18,849 | $1.80 |
| May 20, 2026 | Michael B Hoffman | Buy | 54,933 | $1.90 |
| May 20, 2026 | Michael B Hoffman | Buy | 2,562 | $1.75 |
| May 20, 2026 | Michael B Hoffman | Buy | 18,849 | $1.80 |
| Apr 2, 2026 | Michael B Hoffman | Buy | 713,800 | $2.10 |
| Apr 2, 2026 | Michael B Hoffman | Buy | 713,800 | $2.10 |
| Apr 2, 2026 | Michael B Hoffman | Buy | 713,800 | $2.10 |
ANVS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $-28.85M | -1.40 | $-25.62M |
| Dec 31, 2024 | $0 | $-24.59M | -2.31 | $-21.89M |
| Dec 31, 2023 | $0 | $-56.20M | -6.23 | $-39.97M |
| Dec 31, 2022 | $0 | $-25.33M | -3.10 | $-17.31M |
| Dec 31, 2021 | $0 | $-14.49M | -1.90 | $-9.13M |
Latest balance sheet: total assets $22.04M, total liabilities $26.29M, cash $18.73M (as of Jun 30, 2026).
ANVS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $1.85 |
| May 15, 2026 | 8-K Item 2.02 (results) | $2.06 |
| Mar 16, 2026 | 8-K Item 2.02 (results) | $2.83 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $2.29 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $2.77 |
| May 13, 2025 | 8-K Item 2.02 (results) | $1.70 |
| Mar 21, 2025 | 8-K Item 2.02 (results) | $1.75 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $7.54 |
| Aug 15, 2024 | 8-K Item 2.02 (results) | — |
| May 13, 2024 | 8-K Item 2.02 (results) | — |
| Apr 3, 2024 | 8-K Item 2.02 (results) | — |
| Nov 1, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ANVS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.